综上所述，本研究结果显示，宫颈癌患者总体免疫功能下降且与临床分期关系密切。后续的研究需要增加入组患者数量，增加检测指标，如FoxP3、CD127、CD69、IFN-γ等[17]，同时需要深入研究患者的免疫功能状态与肿瘤进展和预后的相关性，为临床诊断治疗提供实验依据。

    [参考文献]

    [1] Nedergaard BS，Ladekarl M，Nyengaard JR，et al. A comparative study of the cellular immune response in patients with stage IB cervical squamous cell carcinoma. Low numbers of several immune cell subtypes are strongly associated with relapse of disease within 5 years[J]. Gynecol Oncol ......